Why compare them?
Both are represented in Type 2 diabetes research, making their overlapping mechanisms and evidence maturity useful to compare.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Semaglutide vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidencePartial comparison
SURMOUNT-5 directly compared maximum tolerated tirzepatide 10 or 15 mg with semaglutide 1.7 or 2.4 mg for 72 weeks in adults with obesity without diabetes. It did not test Wegovy HD 7.2 mg or compare cardiovascular, kidney, diabetes, MASH, sleep-apnoea, or long-term discontinuation outcomes.
✓ Shared
Shared Similarities
- Both records include GLP-1R.
- Both have been studied in Type 2 diabetes.
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Semaglutide is distinguished in the current record by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceComparable
Semaglutide: Mature human evidence. Tirzepatide: Mature human evidence.
Regulatory historyComparable
Semaglutide: FDA approved for defined product-specific indications. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthTirzepatide
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Receptor activityEvidence, not a winner
SemaglutideGLP-1R
Single GLP-1 receptor agonist.
TirzepatideGIPR + GLP-1R
Dual GIP and GLP-1 receptor agonist.
Direct obesity comparisonEvidence, not a winner
Semaglutide−13.7% at 72 weeks
SURMOUNT-5 maximum tolerated semaglutide 1.7 or 2.4 mg arm.
Tirzepatide−20.2% at 72 weeks
SURMOUNT-5 maximum tolerated tirzepatide 10 or 15 mg arm.
Weight-evidence contextEvidence, not a winner
SemaglutideSeveral products and doses
STEP 1 supports 2.4 mg; STEP UP supports 7.2 mg. SURMOUNT-5 did not test the 7.2 mg Wegovy HD product.
TirzepatideLarge SURMOUNT program
Placebo-controlled and maintenance trials include several studied doses and populations.
Other labeled outcome areasEvidence, not a winner
SemaglutideCV, kidney, MASH
Product-specific U.S. labels include defined cardiovascular, kidney, and accelerated-approval MASH indications.
TirzepatideOSA + diabetes
Product-specific U.S. labels include defined obstructive-sleep-apnoea, weight-management, and diabetes indications.
Administration formatsEvidence, not a winner
SemaglutideWeekly injection + daily tablets
Multiple named products have distinct routes, strengths, indications, and handling instructions.
TirzepatideWeekly injection
Current approved U.S. products are ready-to-use subcutaneous solutions.
Combination boundaryEvidence, not a winner
SemaglutideDirect GLP-1R overlap
Current labels advise against use with another semaglutide-containing product or GLP-1 receptor agonist.
TirzepatideDirect GLP-1R overlap
Current labels advise against use with another GLP-1 receptor agonist.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Partial comparison
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Pathway boundary: Both activate GLP-1R. Tirzepatide also activates GIPR. Using both would create direct GLP-1-receptor overlap; current labels advise against combining the named products with another GLP-1 receptor agonist.
Current unknowns
Questions the evidence cannot answer yet
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
Semaglutide
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.